Clinical trial
HER-2 Protein Vaccine in Treating Women With Breast Cancer
NCT00068614 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00068614 |
|---|---|
| Title | HER-2 Protein Vaccine in Treating Women With Breast Cancer |
| Official title | A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | HER-2/neu peptide vaccine |
| Start date | Jul 1, 2003 |
| Primary completion | Oct 1, 2005 |
| First posted | Sep 11, 2003 |
| Last update posted | Feb 5, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: